linkedin

Driven.
For a Sustainable Life.

Samsung Biologics aspires to lead the industry in protecting our planet for the health of future generations. In our mission to enrich human life while creating enduring and sustainable value, we are investing in practices and technologies to mitigate the risks of climate change in the greater areas we impact. As a global CDMO partner, we recognize the greater impact we can have by working together, and essential to our decarbonization is the cooperation and engagement with our suppliers to accelerate the net zero transition across our supply chains.

A blossom of hope

We are on a journey to help create a healthier adn sustainable future.

Our path to changing the world is never ending.

It touches everyone and everything.

Together we are

Driven. For a Sustainable Life.

Driven. For Life.

Samsung Biologics

ESG Report

We're committed to sharing our
sustainable progress and goals.
Learn more about our sustainability initiatives.

Our Involvements

We are committed to global carbon neutrality

SMI
Sustainable Markets Initiative(SMI)

A low-carbon transition engagement led by the British royal family,
Samsung Biologics participated as a representative of the global CDMO industry
to seek a net-zero supply chain plan

Find out more on the SMI website
The SMI was launched by His Majesty King Charles III at the World Economic Forum in 2020. It aims to lead the transition to a sustainable future by convening leaders to bring economic value into alignment with social and environmental sustainability.
In 2021, the SMI Health Systems Taskforce was formally launched at COP26 in Glasgow including 13 leaders from across the healthcare system with CEOs/equivalents from: AstraZeneca, GSK, Merck, Roche, Samsung Biologics, Sanofi, Novo Nordisk, the World Health Organization, UNICEF, NHS England, the Sustainable Healthcare Coalition, the Karolinska Institute and the University of Pavia.

With its shared ambition to accelerate the delivery of net zero, sustainable healthcare to improve individual, societal and planetary health, the SMI Health Systems Taskforce is committed to delivering action in three priority areas through the establishment of Working Groups:
Supply Chains (championed by John Rim, CEO Samsung Biologics).
The Supply Chains Working Group is focused on accelerating the net zero transition across health systems supply chains. More specifically, the group aims to work with suppliers to decarbonize upstream product supply chains, with a focus on renewable energy, clean heat, green logistics and common supplier standards.
Patient Care Pathways (championed by Paul Hudson, CEO Sanofi).
The Patient Care Pathways Working Group focuses on identifying opportunities to deliver net zero patient care while improving health and societal outcomes. The group aims to demonstrate how interventions across the care pathway can drive emissions reductions by decarbonizing care settings, preventing and managing disease progression, and delivering lower-CO2 solutions.
Digital Healthcare (championed by Belén Garijo, CEO Merck).
The Digital Healthcare Working Group focuses on leveraging digital innovation and technology in order to drive the transition to net zero across health systems. The initial focus of the group is on demonstrating how digital solutions can support reducing emissions across clinical trials while improving patient outcomes and the patient experience.
Frontier 1.5D
The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5°C above pre-industrial levels.
Business leaders from Korea have joined with the British Embassy, Ewha Woman’s University, Financial Supervisory Service, to analyze the financial impact of climate response policies in the effort to address uncertainties associated with climate change and collectively thrive for a net-zero future.

As a business sector representative, Samsung Biologics will be providing data for each of its biopharmaceutical manufacturing plants through its Carbon Disclosure Project (CDP) initiative with Science Based Targets (SBT) to determine risks and opportunities on climate change as well as the financial impact.
Frontier 1.5D

The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5°C above pre-industrial levels.
Business leaders from Korea have joined with the British Embassy, Ewha Woman’s University, Financial Supervisory Service, to analyze the financial impact of climate response policies in the effort to address uncertainties associated with climate change and collectively thrive for a net-zero future.

As a business sector representative, Samsung Biologics will be providing data for each of its biopharmaceutical manufacturing plants through its Carbon Disclosure Project (CDP) initiative with Science Based Targets (SBT) to determine risks and opportunities on climate change as well as the financial impact.

Our Actions

  • Greenhouse Gas
    Reduction in the
    operation site

  • Introduction of
    Renewable
    Energy

  • Offsetting Carbon
    Emissions

  • Value Chain
    emission
    management

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved